parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in podocytes	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	6 Parkinson's papers of 358	0.74
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 6769

receipt 6777: RCAN1 in dopamine neurons, braak

power: full sample -0.01 (p 0.962, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.01 (p 0.962, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.365, n 18). could be the mix.
skeptic: leave-one-out range -0.11 to +0.12, sign flips 6; without severely affected donors -0.01 (p 0.962, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RCAN1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6776: RCAN1 in oligodendrocytes, braak

power: full sample -0.19 (p 0.455, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.21 (p 0.398, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.29 (p 0.243, n 18). could be the mix.
skeptic: leave-one-out range -0.34 to -0.08, sign flips 0; without severely affected donors -0.19 (p 0.455, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RCAN1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts